Michael Bishop

9.6k total citations · 1 hit paper
119 papers, 2.8k citations indexed

About

Michael Bishop is a scholar working on Oncology, Hematology and Electrical and Electronic Engineering. According to data from OpenAlex, Michael Bishop has authored 119 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Oncology, 35 papers in Hematology and 23 papers in Electrical and Electronic Engineering. Recurrent topics in Michael Bishop's work include CAR-T cell therapy research (34 papers), Hematopoietic Stem Cell Transplantation (26 papers) and Lymphoma Diagnosis and Treatment (20 papers). Michael Bishop is often cited by papers focused on CAR-T cell therapy research (34 papers), Hematopoietic Stem Cell Transplantation (26 papers) and Lymphoma Diagnosis and Treatment (20 papers). Michael Bishop collaborates with scholars based in United States, United Kingdom and Germany. Michael Bishop's co-authors include Mitchell S. Cairo, Philip J. Bierman, Anne Kessinger, Julie M. Vose, J R Anderson, Jamés O. Armitage, Benjamin Bunday, Stefano Tarantolo, Mary E. Morris and Wing C. Chan and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Michael Bishop

107 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumour lysis syndrome: new therapeutic strategies and classification

2004 639 citations Mitchell S. Cairo, Michael Bishop British Journal of Haematology profile →

Peers

Countries citing papers authored by Michael Bishop

Since Specialization

Citations

This map shows the geographic impact of Michael Bishop's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Bishop with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Bishop more than expected).

Fields of papers citing papers by Michael Bishop

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Bishop. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Bishop. The network helps show where Michael Bishop may publish in the future.

Co-authorship network of co-authors of Michael Bishop

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Bishop. A scholar is included among the top collaborators of Michael Bishop based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Bishop. Michael Bishop is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Deep Molecular Remission Predicts Better Clinical Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) Treated with Obecabtagene Autoleucel (obe-cel) 2025 ·Transplantation and Cellular Therapy ·(unknown), Jae H. Park, Paul Shaughnessy, Aaron C. Logan, Karamjeet Sandhu, Mehrdad Abedi, Bijal Shah, Michael Bishop, Daniel J. DeAngelo, Pierre Lao‐Sirieix, (unknown), Yiyun Zhang, Claire Roddie	1
2	Healthcare Resource Utilization and Costs Associated with Managing CRS and ICANS in Patients with Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia Receiving Obecabtagene autoleucel (obe-cel) 2024 ·Blood ·Bijal Shah, Jeremy Pantin, Karamjeet Sandhu, Elias Jabbour, Jae H. Park, Paul Shaughnessy, Mehrdad Abedi, Michael Bishop, Daniel J. DeAngelo, (unknown), Martin C. Brown, Dilip Patel, Claire Roddie, Aaron C. Logan	0
3	Long-term survival outcomes of patients (pts) with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3. 2024 ·Journal of Clinical Oncology ·Olalekan O. Oluwole, Armin Ghobadi, Ryan D. Cassaday, Jae H. Park, Roch Houot, Aaron C. Logan, Nicolas Boissel, Thibaut Leguay, Michael Bishop, Max S. Topp, (unknown), Maria R. Baer, Gary J. Schiller, Mehrdad Abedi, Monique C. Minnema, Patrick J. Stiff, (unknown), (unknown), (unknown), Bijal Shah	3
4	Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Deep Molecular Remission May Predict Better Outcomes 2024 ·Blood ·(unknown), Jae H. Park, Paul Shaughnessy, Aaron C. Logan, Karamjeet Sandhu, Mehrdad Abedi, Bijal Shah, Michael Bishop, Daniel J. DeAngelo, Pierre Lao‐Sirieix, (unknown), Martin Pulé, Yiyun Zhang, Claire Roddie	1
5	Obecabtagene autoleucel (obe-cel, AUTO1) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL): Overall survival (OS), event-free survival (EFS) and the potential impact of chimeric antigen receptor (CAR)-T cell persistency and consolidative stem cell transplantation (SCT) in the open-label, single-arm FELIX phase Ib/II study. 2024 ·Journal of Clinical Oncology ·Elias Jabbour, Eleni Tholouli, Karamjeet Sandhu, Paul Shaughnessy, Pere Barba, Manuel Guerreiro, Deborah Yallop, Aaron C. Logan, Mehrdad Abedi, Pierre Lao‐Sirieix, Yiyun Zhang, (unknown), Martin Pulé, Bijal Shah, Michael Bishop, Jae H. Park, Daniel J. DeAngelo, Karl S. Peggs, Claire Roddie	8
6	Prolonged Cytopenias after Commercial CAR T-Cell Therapy with Tisagenlecleucel and Axicabtagene Ciloleucel for Relapsed and Refractory DLBCL 2023 ·Transplantation and Cellular Therapy ·(unknown), (unknown), Staci Williamson, Jamie Brower, Veronika Bachanová, Joseph P. McGuirk, Loretta J. Nastoupil, Olalekan O. Oluwole, David Porter, Peter A. Riedell, Michael Bishop, Miguel‐Angel Perales, Richard T. Maziarz	1
7	Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States 2022 ·Advances in Therapy ·Bijal Shah, Nathaniel Smith, Chaoling Feng, (unknown), (unknown), (unknown), Behzad Kharabi Masouleh, Daniel C. Malone, Michael Bishop	6
8	Host Lymphocyte Depletion as a Strategy to Facilitate Early Full Donor Chimerism after Reduced-Intensity Allogeneic Stem Cell Transplantation 2013 ·Biology of Blood and Marrow Transplantation ·Rachel B. Salit, Daniel H. Fowler, Robert M. Dean, Steven Z. Pavletic, Frances T. Hakim, Seth M. Steinberg, (unknown), Claude Sportès, Ronald E. Gress, Michael Bishop	5
9	Strategies to Improve Long-Term Outcome in Stage IIIB Inflammatory Breast Cancer: Multimodality Treatment Including Dose-Intensive Induction and High-Dose Chemotherapy 2009 ·Biology of Blood and Marrow Transplantation ·Claude Sportès, Seth M. Steinberg, David J. Liewehr, Juan Gea‐Banacloche, David N. Danforth, Daniele Avila, (unknown), Michael Krumlauf, Daniel H. Fowler, Steven Z. Pavletic, Nancy M. Hardy, Michael Bishop, Ronald E. Gress	7
10	Vulvovaginal Chronic Graft-Versus-Host Disease With Allogeneic Hematopoietic Stem Cell Transplantation 2007 ·Obstetrics and Gynecology ·Pamela Stratton, Maria L. Turner, Richard Childs, John Barrett, Michael Bishop, Alan S. Wayne, Steven Z. Pavletic	54
11	Allogeneic Lymphocytes Induce Tumor Regression of Advanced Metastatic Breast Cancer 2004 ·Journal of Clinical Oncology ·Michael Bishop, Daniel H. Fowler, (unknown), Kathleen M. Castro, Claude Kasten-Sportès, Seth M. Steinberg, Juan Gea‐Banacloche, Robert M. Dean, Catherine K. Chow, Charles W. Carter, Elizabeth J. Read, Susan F. Leitman, Ronald E. Gress	74
12	Determination of optimal parameters for CD-SEM measurement of line-edge roughness 2004 ·Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE ·Benjamin Bunday, Michael Bishop, (unknown), John S. Villarrubia, András Vládar, Ronald G. Dixson, Theodore V. Vorburger, Ndubuisi G. Orji, John A. Allgair	64
13	Tumour lysis syndrome: new therapeutic strategies and classification breakdown → 2004 ·British Journal of Haematology ·Mitchell S. Cairo, Michael Bishop	639
14	Allogeneic Hematopoietic Stem Cell Transplantation for Lymphoma 2004 ·Clinical Lymphoma ·Robert M. Dean, Michael Bishop	5
15	CD-SEM measurement line-edge roughness test patterns for 193-nm lithography 2003 ·Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE ·Benjamin Bunday, Michael Bishop, John S. Villarrubia, András Vládar	21
16	Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas 2003 ·Biology of Blood and Marrow Transplantation ·Michael Bishop, (unknown), Wyndham H. Wilson, Seth M. Steinberg, Jeanne Odom, Kathleen M. Castro, Claude Kasten-Sportès, Juan Gea‐Banacloche, (unknown), Ronald E. Gress, Daniel H. Fowler	4
17	High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma 1998 ·Annals of Oncology ·Ž Pavletić, Philip J. Bierman, Julie M. Vose, Michael Bishop, Chaowei Wu, J Pierson, J Kollath, DD Weisenburger, Anne Kessinger, Jamés O. Armitage	58
18	Ex Vivo Treatment of Bone Marrow with Phosphorothioate Oligonucleotide OL(l)p53 for Autologous Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndrome 1997 ·Journal of Hematotherapy ·Michael Bishop, Jonathan Jackson, Stefano Tarantolo, (unknown), Patrick L. Iversen, Eliel Bayever, (unknown), John Sharp, J Pierson, Phyllis I. Warkentin, Jamés O. Armitage, Anne Kessinger	20
19	Combination of antisense oligonucleotide and low-dose chemotherapy in hematological malignancies 1997 ·Journal of Pharmacological and Toxicological Methods ·Eric J. Benner, Michael Bishop, (unknown), Patrick L. Iversen, S. K. Joshi	10
20	Peripheral Stem Cell Transplantation in Non-Hodgkin's Lymphoma Patients 1993 ·Journal of Hematotherapy ·Anne Kessinger, Julie M. Vose, Philip J. Bierman, Michael Bishop, Jamés O. Armitage	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact